A key advantage of these blood tests is their specific ability to identify the amyloid and tau pathology of Alzheimer disease in accordance with the “A” and “T” respective amyloid and tau components of the current biomarker research framework (Jack et al., 2018). Here, MAPT is linked to Alzheimer disease.